GlassScriptPhysician profile
Elliot Ellis
NPI 1396914800
$4,777.52
in general payments reported to CMS, 2019-2025
26 companies · $1,067 in 2025
The $1,067 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $469 · 2021: $960 · 2022: $535 · 2023: $300 · 2024: $338 · 2025: $1,067.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $932.94 | 2019-2025 | |
| Janssen Biotech, INC. | $613.48 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $525.52 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.71 | 2019-2022 | |
| Braintree Laboratories, INC. | $317.92 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $312.24 | 2019-2025 | Entyvio |
| Redhill Biopharma INC. | $255.75 | 2021-2022 | |
| Abbott Laboratories | $201.75 | 2025 | Navitor |
| Lilly USA, LLC | $170.27 | 2023-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $161.93 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $123.39 | 2021 | |
| Ucb, INC. | $118.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $118.19 | 2019-2022 | |
| Cleerly, INC. | $102.16 | 2023 | |
| Celgene Corporation | $100.00 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $76.28 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $59.74 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $46.29 | 2019-2022 | |
| Allergan, INC. | $35.91 | 2019-2020 | |
| Vivus LLC | $35.43 | 2021-2025 | Pancreaze |
| Genzyme Corporation | $28.51 | 2024 | |
| Amgen INC. | $23.65 | 2022 | |
| Shire North American Group INC | $21.01 | 2019 | |
| Fresenius Kabi USA, LLC | $20.33 | 2023 | |
| Biocon Biologics INC | $19.08 | 2025 | Yesintek |
| Fujifilm Healthcare Americas Corporation | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elliot Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.